



Favourable, unfavourable and non prognostic markers for human cancers

The identification of cancer markers using primary antibodies is a widely used strategy in cancer diagnostics, screening and research. Tumor marker-specific antibodies can be used to detect elevated quantities of tumor markers in patients' blood, urine or tissue, for cancer diagnosis and prognostic evaluation. Each tumor marker may be associated with more than one type of cancer.

The schematic summarizes some monoclonal antibodies from Atlas Antibodies classified as prognostic genes with regard to cancer type and association with favourable or unfavourable clinical outcome. The classification is based according to the Pathology Atlas, part of the Human Protein Atlas (proteinatlas.org). Our website provides easy access to all characterization data, and online ordering at order@atlasantibodies.com.



DESIGNED BY RESEARCHERS FOR RESEARCHERS



● Glioma

- Anti-B3GAT1 (AMAb91575) *Not prognostic*
- Anti-B3GAT1 (AMAb91576) *Not prognostic*
- Anti-IL411 (AMAb91560) *Unfavourable*

● Head and Neck Cancer

- Anti-CDK2 (AMAb91497) *Unfavourable*
- Anti-IL10RA (AMAb91503) *Favourable*
- Anti-NR5A1(AMAb91540) *Not prognostic*
- Anti-TNFRSF18 (AMAb91487) *Favourable*

● Thyroid Cancer

- Anti-B3GAT1 (AMAb91575) *Not prognostic*
- Anti-B3GAT1 (AMAb91576) *Not prognostic*
- Anti-BCL2 (AMAb91492) *Unfavourable*

● Breast Cancer

- Anti-KRT5 (AMAb91549) *Favourable*
- Anti-IL10RA (AMAb91503) *Not prognostic*
- Anti-ZNF10 (AMAb91592) *Favourable*
- Anti-ZNF10 (AMAb91593) *Favourable*

● Lung Cancer

- Anti-PIEZO1 (AMAb91589) *Unfavourable*
- Anti-PLK1 (AMAb91515) *Unfavourable*

● Liver Cancer

- Anti-AFP (AMAb91610) *Not prognostic*
- Anti-AFP (AMAb91611) *Not prognostic*
- Anti-AR (AMAb91547) *Favourable*
- Anti-ATG5 (AMAb91582) *Unfavourable*
- Anti-BAX (AMAb91490) *Unfavourable*
- Anti-CDK2 (AMAb91497) *Unfavourable*
- Anti-CDK4 (AMAb91499) *Unfavourable*
- Anti-FOLH1(AMAb91551) *Favourable*
- Anti-FOLH1(AMAb91552) *Favourable*
- Anti-GLS2 (AMAb91483) *Not prognostic*
- Anti-GLS2 (AMAb91485) *Not prognostic*
- Anti-HDAC5 (AMAb91501) *Unfavourable*
- Anti-KRT20 (AMAb91564) *Unfavourable*
- Anti-PIK3CB (AMAb91585) *Unfavourable*
- Anti-PLK1 (AMAb91515) *Unfavourable*
- Anti-SMAD2 (AMAb91520) *Unfavourable*
- Anti-SPAG5 (AMAb91605) *Unfavourable*

● Renal Cancer

- Anti-AR (AMAb91547) *Favourable*
- Anti-ATG5 (AMAb91582) *Unfavourable*
- Anti-BCL2 (AMAb91492) *Favourable*
- Anti-CDK2 (AMAb91497) *Unfavourable*
- Anti-CDK4 (AMAb91499) *Unfavourable*
- Anti-CHEK2 (AMAb91570) *Unfavourable*
- Anti-FOLH1 (AMAb91551) *Unfavourable*
- Anti-GATA3 (AMAb91525) *Unfavourable*
- Anti-HDAC5 (AMAb91501) *Favourable*
- Anti-IL10RA (AMAb91503) *Unfavourable*
- Anti-IL411 (AMAb91560) *Unfavourable*
- Anti-KRT20 (AMAb91564) *Unfavourable*
- Anti-KRT7 (AMAb91530) *Favourable*
- Anti-MTOR (AMAb91508) *Favourable*
- Anti-MYO10 (AMAb91554) *Favourable*
- Anti-NFKB2 (AMAb91511) *Unfavourable*
- Anti-PIEZO1 (AMAb91589) *Unfavourable*
- Anti-PLK1 (AMAb91515) *Unfavourable*
- Anti-PROM1 (AMAb91494) *Favourable*
- Anti-SAA1 (AMAb91543) *Unfavourable*
- Anti-SETD2 (AMAb91603) *Favourable*
- Anti-SMAD4 (AMAb91594) *Favourable*
- Anti-SPAG5 (AMAb91605) *Unfavourable*
- Anti-TNFRSF18 (AMAb91487) *Unfavourable*

● Colorectal Cancer

- Anti-AMACR (AMAb91561) *Favourable*
- Anti-AMACR (AMAb91562) *Favourable*
- Anti-MUC2 (AMAb91542) *Not prognostic*
- Anti-MUC5AC (AMAb91539) *Not prognostic*
- Anti-NFKB2 (AMAb91511) *Unfavourable*

● Ovarian Cancer

- Anti-CTAG1B (AMAb91606) *Not prognostic*
- Anti-CTAG1B (AMAb91607) *Not prognostic*
- Anti-FGF18 (AMAb91480) *Not prognostic*
- Anti-KRT7 (AMAb91530) *Unfavourable*
- Anti-KRT7 (AMAb91531) *Unfavourable*
- Anti-NR5A1 (AMAb91540) *Not prognostic*
- Anti-PIEZO1 (AMAb91589) *Unfavourable*

● Pancreatic Cancer

- Anti-FRMD5 (AMAb91580) *Unfavourable*
- Anti-KRT7 (AMAb91530) *Unfavourable*
- Anti-KRT7 (AMAb91531) *Unfavourable*
- Anti-MUC1 (AMAb91533) *Unfavourable*
- Anti-MUC2 (AMAb91542) *Not prognostic*
- Anti-PIK3CB (AMAb91585) *Unfavourable*
- Anti-SPAG5 (AMAb91605) *Unfavourable*

● Prostate Cancer

- Anti-B3GAT1(AMAb91575) *Not prognostic*
- Anti-B3GAT1(AMAb91576) *Not prognostic*
- Anti-KLK3 (AMAb91567) *Not prognostic*
- Anti-KLK3 (AMAb91569) *Not prognostic*
- Anti-POU5F1 (AMAb91477) *Favourable*

● Testis Cancer

- Anti-AFP (AMAb91610) *Not prognostic*
- Anti-AFP (AMAb91611) *Not prognostic*
- Anti-CTAG1B (AMAb91606) *Not prognostic*
- Anti-CTAG1B (AMAb91607) *Not prognostic*
- Anti-DDX53 (AMAb91489) *Not prognostic*
- Anti-NR5A1 (AMAb91540) *Not prognostic*

● Endometrial Cancer

- Anti-PAX2 (AMAb91573) *Unfavourable*
- Anti-PAX8 (AMAb91488) *Unfavourable*
- Anti-PGR (AMAb91529) *Favourable*
- Anti-SCGB2A2 (AMAb91536) *Favourable*
- Anti-TNFRSF18 (AMAb91487) *Favourable*

● Cervical Cancer

- Anti-BCL2 (AMAb91492) *Favourable*
- Anti-HDAC5 (AMAb91501) *Favourable*
- Anti-MYO10 (AMAb91554) *Unfavourable*
- Anti-MYO10 (AMAb91557) *Unfavourable*
- Anti-MYO10 (AMAb91558) *Unfavourable*

Atlas Antibodies logo, Triple A Polyclonals, PrecisA Monoclonals, PrEST Antigen and QPrEST are trademarks or registered trademarks of Atlas Antibodies AB. All other trademarks are the property of their respective owners. Products are for research use only. Not for use in diagnostic procedures. © Atlas Antibodies AB 2020.